iRhythm Holdings, Inc.

iRhythm Holdings, Inc. announced it will release its financial results for the second quarter of 2026 after the close of trading on Thursday, August 6, 2026. The company's management team will host a conference call on the same day at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. A webcast of the conference call will be available on the investor section of iRhythm's website.

iRhythm Holdings, Inc. identified unauthorized activity on certain third-party-hosted business applications on June 8, 2026, leading to a material cybersecurity incident. A threat actor claimed to have exfiltrated sensitive information, including proprietary data, patient protected health information, and other personal information, demanding payment. The company confirmed data exfiltration and deemed the incident material on June 10, 2026, due to the volume of potentially affected data. Despite the breach, iRhythm has not identified any impact to its products, clinical systems, patient safety, operations, or financial reporting, and believes the incident is not reasonably likely to materially impact its financial condition or results of operations.

iRhythm Technologies, a wholly owned subsidiary of iRhythm Holdings, Inc., has entered into a binding Settlement Agreement to fully resolve a previously-disclosed putative class action securities litigation. The settlement involves a payment of $45 million, which the company expects will be largely covered by its directors and officers insurance policies. This resolution will lead to the complete dismissal of the action without any admission of fault by the defendants, and the company does not anticipate an impact on its adjusted non-GAAP financial measures.

iRhythm Holdings, Inc. held its 2026 Annual Meeting of Stockholders on May 27, 2026, where several key proposals were approved. Stockholders elected nine directors, approved the 2026 Equity Incentive Plan, and ratified the appointment of KPMG LLP as the independent registered public accounting firm. Additionally, an amendment to the Certificate of Incorporation to remove the pass-through voting provision was approved, along with an advisory vote on executive compensation.

iRhythm Holdings, Inc. announced its participation in two upcoming investor conferences in June 2026. The company will present at the William Blair 46th Annual Growth Stock Conference on June 2 and the Truist Securities MedTech Conference on June 16. Interested parties can access live and archived webcasts of these presentations via iRhythm's investor website.

iRhythm Holdings, Inc. reported a strong increase in revenue for the first quarter of 2026, rising 25.7% year-over-year to $199.4 million. The company also significantly narrowed its net loss to $13.9 million, or $0.43 per share, compared to a $30.7 million loss in the prior year period. However, net cash used in operating activities increased substantially, indicating higher operational cash burn despite improved profitability metrics. The company also completed a corporate holding company restructuring in January 2026.

iRhythm Holdings reported strong first-quarter 2026 financial results, with revenue increasing 25.7% to $199.4 million and gross margin expanding to 70.9%. The company significantly improved its net loss to $13.9 million and achieved positive adjusted EBITDA of $14.1 million. iRhythm also raised its fiscal year 2026 revenue guidance to $875 million-$885 million and adjusted EBITDA margin to 12.0%-13.0%, driven by robust volume growth and operational efficiencies.

iRhythm Holdings, Inc. announced results from two real-world retrospective analyses presented at HRS 2026, demonstrating the superior detection capabilities of its Zio ambulatory ECG devices. The studies in post-ablation and pregnancy patient populations showed that Zio's continuous 14-day monitoring detected a significant proportion of arrhythmias (26% of AF recurrence post-ablation, 60% of arrhythmias in pregnancy) beyond 48 hours, which would be missed by short-duration Holter monitoring. These findings reinforce the clinical value of Zio devices for a more complete assessment of arrhythmia burden.

iRhythm Holdings, Inc. announced it will release its first quarter 2026 financial results after the close of trading on Thursday, April 30, 2026. Following the release, the company's management team will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. Interested parties can access the live and archived webcast on the "Quarterly Results" section of iRhythm's investor website.